Researchers found that COVID-19 mRNA vaccines, when given within 100 days of starting immune checkpoint inhibitors, were ...

Over the past 35 years, interferons have been explored in various formulations for the management of Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs), such as essential ...

Unlike antibody-producing B cells that help fight the current infection, the long-lived, non-circulating lung-BRMs migrate to the lungs from draining lymph nodes. They reside there permanently and lie ...

These intercellular messages, ferried about by molecules called interferons, serve as a warning signal to nearby cells—“‘You are about to be infected; it’s time for you to set up an antiviral state,’” ...

The pandemic is not over, despite some proclamations to the contrary. The good news is that we now have some effective therapeutics that are helping drive fatality rates down. Chief among these is ...

The current medicine chest for treating COVID-19 is fairly sparse. Only one drug—remdesivir—is approved by the U.S. Food and Drug Administration (FDA), and three—Paxlovid, molnupiravir, and ...

Figure 1. The direct-acting antiviral targets in the hepatitis C virus replication cycle. NS3/4A protease inhibitors target the NS3/4A protease enzyme which is needed for the virus to develop the ...

Background and objectives Peginterferon-α treatment exhibits low rates of the serological conversion rate of hepatitis B e ...

Peginterferon-α treatment exhibits low rates of the serological conversion rate of hepatitis B e antigen (HBeAg) and the negative conversion rate of ...